2.4.0.8070100 - Disclosure - DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)truefalsefalse1false falsefalsec20130101to20130630http://www.sec.gov/CIK0001070698duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_AccountingPoliciesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES [Abstract]2false 2us-gaap_FiscalPeriodus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Change in Fiscal Year End</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">In December 2012, Raptor's board of directors approved a change in the Company's fiscal year end from August 31 to December 31. The accompanying condensed consolidated financial statements cover the period from January 1, 2013 through June 30, 2013, representing the first six months of Raptor's newly adopted fiscal year. The prior year's comparable six month period covers December 1, 2011 through May 31, 2012, which is reported on the basis of Raptor's previous fiscal year end. As a result of the change in Raptor's fiscal year end, the quarterly periods of Raptor's newly adopted fiscal year do not coincide with the historical quarterly periods that Raptor had previously reported. The Company did not recast the results for the 2012 fiscal periods because the financial reporting processes in place at the time included certain procedures that were only performed on a quarterly basis. Consequently, to recast these periods would have been impractical and would not have been cost-justified. The Company believes the comparative information provided for the three and six month periods ended May 31, 2012 provides a meaningful comparison to the three and six month periods ended June 30, 2013 and there are no factors, seasonal or otherwise, that materially impact the comparability of information or trends.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph k -Article 1 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=7656940&loc=d3e5291-111683 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section S99 -Paragraph 3 -Subparagraph (SX 210.3A-03.(b)) -URI http://asc.fasb.org/extlink&oid=6959686&loc=d3e355100-122828 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.3A-02.(b)) -URI http://asc.fasb.org/extlink&oid=6959686&loc=d3e355033-122828 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 4 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph b -Article 3A Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 06 -Article 3 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph b -Article 3A false0Change in Fiscal Year End3false 2us-gaap_BasisOfAccountingPolicyPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div><div><div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic; text-align: justify; text-indent: 36pt;">Basis of Presentation</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">The accompanying condensed consolidated financial statements reflect the results of operations of Raptor and have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") and in conjunction with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and footnotes required by GAAP for complete financial statements. In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments (including normal recurring accruals) considered necessary for the fair presentation of the Company's consolidated financial position, results of operations and cash flows for the periods presented. This Form 10-Q should be read in conjunction with the audited financial statements and accompanying notes in the Company's Transition Report on Form 10-KT for the four-month period ended December 31, 2012, as amended.</div><div style="font-family: 'Times New Roman', Times, serif;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">The Company's condensed consolidated financial statements include the accounts of the Company's direct and indirect wholly owned subsidiaries, Raptor Pharmaceuticals Inc., formerly known as Raptor Therapeutics Inc. which merged with Raptor Discoveries Inc. in December 2012 prior to changing its name and Raptor European Products, LLC, such subsidiaries incorporated in Delaware on August 1, 2007, and February 14, 2012, respectively, and Raptor Pharmaceuticals Europe B.V. (domiciled in the Netherlands and formed on December 15, 2009), Raptor Pharmaceuticals France SAS (incorporated in France on October 30, 2012) and RPTP European Holdings C.V. (located in the Grand Caymans and formed on February 16, 2012). All intercompany accounts have been eliminated. The Company's condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. Through June 30, 2013, the Company had accumulated losses of approximately $176.0 million. Management expects to incur further losses for the foreseeable future.</div><div style="font-family: 'Times New Roman', Times, serif;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">The Company believes that based upon its projected PROCYSBI sales and planned operations, its cash and cash equivalents as of June 30, 2013 of approximately $74.6 million and net cash proceeds of approximately $11.2 million received in July 2013 from sales of common stock under its "at-the-market" ("ATM") offering will be sufficient to meet its projected operational requirements and obligations through the end of 2014.</div></div></div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).No definition available.false0Basis of Presentation4false 2us-gaap_UseOfEstimatesus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Use of Estimates</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 94-6 -Paragraph 11, 14 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Use of Estimates5false 2us-gaap_RevenueRecognitionPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Revenue Recognition</div><div><br /></div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company recognizes revenue in accordance with the FASB ASC 605, <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Revenue Recognition</font>, when the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred and risk of loss has passed; the seller's price to the buyer is fixed or determinable and collectability is reasonably assured. The Company determines that persuasive evidence of an arrangement exists based on written contracts that defined the terms of the arrangements. Pursuant to the contract terms, the Company determines when title to products and associated risk of loss has passed onto the customer. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. The Company assesses collectability based primarily on the customer's payment history and on the creditworthiness of the customer. Without sufficient credit history, the Company determines a customary collectability percentage.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">PROCYSBI is currently only available for distribution from the Company's specialty pharmacy partner, which ships directly to the patient. PROCYSBI is not available in retail pharmacies. Prior authorization of coverage level by the patient's private insurance plan or government payor is a prerequisite to the shipment of PROCYSBI to a patient. Revenue is recognized once the product has been shipped by the specialty pharmacy and receipt confirmed by the patient.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company records revenue net of expected discounts, distributor fees, rebates, including those paid to government agencies, and returns. Allowances are recorded as a reduction of revenue at the time product sales are recognized. Allowances for government rebates and discounts are established based on the actual payor information, which is known at the time of shipment, and the government-mandated discounts applicable to government-funded programs.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section B -Paragraph Question 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.B.Q1) -URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 22 -Paragraph 8, 12, 13 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790 false0Revenue Recognition6false 2rptp_InventoryAndCostOfSalesPolicyPolicyTextBlockrptp_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Inventories and Cost of Sales</div><div><br /></div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Inventories are stated at the lower of cost or market price with cost determined on a first-in, first-out basis. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on sales activity, both projected and historical, as well as product shelf-life. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the probability that revenue will be obtained from the future sale of the related inventory. Prior to the approval of PROCYSBI by the FDA on April 30 2013, the Company recorded manufacturing costs relating to PROCYSBI as research and development expense. Subsequent to approval, the Company began capitalizing these costs as commercial inventory. As of June 30, 2013, the Company's capitalized inventory was approximately $0.2 million, all of which was considered finished goods. Upon launching PROCYSBI in mid-June 2013, the Company began recognizing costs of sales. During the quarter ended June 30, 2013, the Company recorded $0.4 million as cost of sales representing commercial inventory that was capitalized subsequent to FDA approval but written off due to an unanticipated minor change in the finished product presentation which is not expected to be repeated in the future. Cost of sales includes the cost of inventory sold and reserved, manufacturing and supply chain costs, product shipping and handling costs, amortization of licensing approval milestone payments and licensing royalties payable to the University of California, San Diego ("UCSD").</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for inventory and cost of sales.No definition available.false0Inventories and Cost of Sales7false 2us-gaap_ComprehensiveIncomePolicyPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Comprehensive Loss</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Components of comprehensive loss are reported in the Company's Condensed Consolidated Statements of Comprehensive Loss in the period in which they are recognized. The components of comprehensive loss include net loss and foreign currency translation adjustments.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for comprehensive income.No definition available.false0Comprehensive Loss8false 2us-gaap_CashAndCashEquivalentsPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Cash and Cash Equivalents</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company considers all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. The Company maintains cash and cash equivalents, which consist principally of money market funds with high credit quality financial institutions. Such amounts exceed Federal Deposit Insurance Corporation insurance limits. Restricted cash represents compensating balances required by the Company's U.S. and European banks as collateral for credit cards.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 305 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2122427 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Financial Reporting Release (FRR) -Number 203 -Paragraph 02-03 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Technical Practice Aid (TPA) -Number 2110 -Paragraph 6 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 8, 9, 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Cash and Cash Equivalents9false 2rptp_ShortTermInvestmentsPolicyTextBlockrptp_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Short-term Investments</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company typically invests in short-term investments in high credit-quality funds in order to obtain higher yields on its cash available for investment. Short-term investments were $0 and approximately $22.1 million, as of June 30, 2013 and December 31, 2012, respectively. The Company is currently evaluating its short-term investment fund options and in the future may invest a portion of its cash and cash equivalents balance ($74.6 million as of June 30, 2013) in high credit-quality, and high-yielding short-term investment funds.</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Such investments are not insured by the Federal Deposit Insurance Corporation. The Company completed an evaluation of its investments and determined that it did not have any other-than-temporary impairments at December 31, 2012. The investments were placed in financial institutions with strong credit ratings.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for short-term investments.No definition available.false0Short-term Investments10false 2us-gaap_TradeAndOtherAccountsReceivablePolicyus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Accounts Receivable</div><div><br /></div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Trade accounts receivable are recorded net of product sales allowances for prompt-payment discounts, chargebacks and doubtful accounts. Estimates for chargebacks and prompt-payment discounts are based on contractual terms and the Company's expectations regarding the utilization rates. As of June 30, 2013, the Accredo Health Group, Inc. ("Accredo"), Raptor's exclusive distributor in the U.S., is the Company's only significant customer for PROCYSBI in the U.S.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables. If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3, 4 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 01-6 -Paragraph 13 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=7512638&loc=d3e5093-111524 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6378556&loc=d3e10133-111534 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 50 -Paragraph 15 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=7512638&loc=d3e5212-111524 false0Accounts Receivable11false 2us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Functional Currency</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company's consolidated functional currency is the U.S. dollar. Raptor Pharmaceuticals Europe B.V. ("BV"), Raptor Pharmaceuticals France SAS ("SAS") and RPTP European Holdings C.V. ("CV"), the Company's European subsidiaries and Cayman-based subsidiary, respectively, use the European Euro as their functional currency. At each quarter end, BV's, SAS's and CV's balance sheets are translated into U.S. dollars based upon the quarter-end exchange rate, while their statements of comprehensive loss are translated into U.S. dollars based upon an average of the Euro's value between the beginning and end date of the reporting period. BV's, SAS's and CV's equity are adjusted for any translation gain or loss.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 20 -URI http://asc.fasb.org/subtopic&trid=2175856 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2175826 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -URI http://asc.fasb.org/subtopic&trid=2175892 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 52 -Paragraph 5, 7-20, 80 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Functional Currency12false 2us-gaap_FairValueOfFinancialInstrumentsPolicyus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value of Financial Instruments</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The carrying amounts of certain of the Company's financial instruments including cash and cash equivalents, restricted cash, prepaid expenses, accounts payable, accrued liabilities and capital lease liability approximate fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these condensed consolidated financial statements. The warrant liability is carried at fair value which is determined using the Black-Scholes option valuation model at the end of each reporting period.</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company uses a fair value approach to value certain assets and liabilities. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The hierarchy consists of three levels:</div><div><br /></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 36pt; vertical-align: top; align: right;"><div style="text-align: left; font-family: symbol, serif; margin-left: 18pt; font-size: 10pt;">&#183;</div></td><td style="width: auto; vertical-align: top;"><div style="text-align: justify; font-family: ''times new roman'', times, serif; font-size: 10pt;">Level one - Quoted market prices in active markets for identical assets or liabilities;</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 36pt; vertical-align: top; align: right;"><div style="text-align: left; font-family: symbol, serif; margin-left: 18pt; font-size: 10pt;">&#183;</div></td><td style="width: auto; vertical-align: top;"><div style="text-align: justify; font-family: ''times new roman'', times, serif; font-size: 10pt;">Level two - Inputs other than level one inputs that are either directly or indirectly observable; and</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 36pt; vertical-align: top; align: right;"><div style="text-align: left; font-family: symbol, serif; margin-left: 18pt; font-size: 10pt;">&#183;</div></td><td style="width: auto; vertical-align: top;"><div style="text-align: justify; font-family: ''times new roman'', times, serif; font-size: 10pt;">Level three - Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.</div></td></tr></table></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><!--Anchor-->Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. Assets and liabilities measured at fair value on a recurring basis at June 30, 2013 and December 31, 2012 are summarized as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: left; font-style: italic; font-family: ''times new roman'', times, serif; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">(In thousands)</div></td><td colspan="3" valign="bottom" style="vertical-align: top;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: top;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: top;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: top;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: top;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: top;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: top;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: top;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Assets</div></td><td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''times new roman'', times, serif; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">Level 1</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''times new roman'', times, serif; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">Level 2</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''times new roman'', times, serif; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">Level 3</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''times new roman'', times, serif; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">June 30, 2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td><td colspan="3" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;">&#160;</td></tr><tr><td bgcolor="#cceeff" valign="bottom" style="width: 52%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">Fair value of cash equivalents</div></td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">69,142</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">69,142</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td></tr><tr><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">Restricted cash</div></td><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">213</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">213</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td></tr><tr><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 52%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">Total</div></td><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">69,142</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">213</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">69,355</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td></tr><tr><td bgcolor="#ffffff" valign="bottom" style="width: 52%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td bgcolor="#ffffff" valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: right; width: 9%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: right; width: 9%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: right; width: 9%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: right; width: 9%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td></tr><tr><td bgcolor="#cceeff" valign="bottom" style="width: 52%; vertical-align: bottom;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Liabilities</div></td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">Fair value of common stock warrants</div></td><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">13,468</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">13,468</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td></tr><tr><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 52%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">Total</div></td><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">13,468</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">13,468</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td></tr><tr><td bgcolor="#ffffff" valign="bottom" style="width: 52%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td bgcolor="#ffffff" valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: right; width: 9%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: right; width: 9%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: right; width: 9%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: right; width: 9%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td></tr><tr><td bgcolor="#cceeff" valign="bottom" style="width: 52%; vertical-align: bottom;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Assets</div></td><td bgcolor="#ffffff" colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''times new roman'', times, serif; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">Level 1</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td bgcolor="#ffffff" colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''times new roman'', times, serif; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">Level 2</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td bgcolor="#ffffff" colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''times new roman'', times, serif; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">Level 3</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td bgcolor="#ffffff" colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''times new roman'', times, serif; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">December 31, 2012</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td></tr><tr><td bgcolor="#cceeff" valign="bottom" style="width: 52%; vertical-align: bottom;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td bgcolor="#ffffff" valign="bottom" style="width: 52%; vertical-align: bottom;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">Fair value of cash equivalents</div></td><td bgcolor="#ffffff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#ffffff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">35,069</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#ffffff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#ffffff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#ffffff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">35,069</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td bgcolor="#cceeff" valign="bottom" style="width: 52%; vertical-align: bottom;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">Restricted cash</div></td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">163</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">163</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">Short-term investments</div></td><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">22,096</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">22,096</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td></tr><tr><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 52%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">Total</div></td><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">57,165</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">163</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">57,328</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td></tr><tr><td bgcolor="#ffffff" valign="bottom" style="width: 52%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td bgcolor="#ffffff" valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: right; width: 9%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: right; width: 9%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: right; width: 9%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="text-align: right; width: 9%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td></tr><tr><td bgcolor="#cceeff" valign="bottom" style="width: 52%; vertical-align: bottom;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">Liabilities</div></td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;">&#160;</td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">Fair value of common stock warrants</div></td><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">16,405</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#ffffff" valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">16,405</div></td><td bgcolor="#ffffff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td></tr><tr><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 52%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">Total</div></td><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">0</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">16,405</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">$</div></td><td bgcolor="#cceeff" valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: top;"><div style="font-family: ''times new roman'', times, serif; font-size: 10pt;">16,405</div></td><td bgcolor="#cceeff" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: top;">&#160;</td></tr></table></div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for determining the fair value of financial instruments.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2155942 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 107 -Paragraph 8, 10, 12, 13, 14 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Fair Value of Financial Instruments13false 2us-gaap_IntangibleAssetsFiniteLivedPolicyus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Intangible Assets</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Intangible assets include the intellectual property and other rights relating to DR Cysteamine (developed as PROCYSBI and RP103), capitalized licensing milestone payments to UCSD based upon drug approval and to an out-license acquired in the merger of the Company's subsidiary with and into Raptor Pharmaceuticals Corp. in September 2009 ("2009 Merger"). The intangible assets related to intellectual property of PROCYSBI/RP103 are amortized using the straight-line method over the estimated useful life of 20 years, which is the life of the intellectual property patents. The 20-year estimated useful life is also based upon the typical development, approval, marketing and life cycle management timelines of pharmaceutical drug products. Licensing milestone payments are amortized upon relevant regulatory approval through 2027, the remaining life of the patent. Intangible assets related to the out-license are amortized using the straight-line method over the estimated useful life of 16 years, which is the life of the intellectual property patents.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -URI http://asc.fasb.org/subtopic&trid=2144471 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 7-18, 22 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 11-15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Intangible Assets14false 2us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicyus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Goodwill</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Goodwill represents the excess of the value of the purchase consideration over the identifiable assets acquired in the 2009 Merger. Goodwill is reviewed annually, or when an indication of impairment exists. When an impairment analysis is performed, if deemed necessary, a write-down in valuation is recorded.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -URI http://asc.fasb.org/subtopic&trid=2144439 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 18-23, 26, 34 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Goodwill15false 2us-gaap_PropertyPlantAndEquipmentPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Fixed Assets</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Fixed assets, which mainly consist of leasehold improvements, furniture and fixtures, lab equipment, computer hardware and software and capital lease equipment, are stated at cost. Depreciation is computed using the straight-line method over the related estimated useful lives, except for leasehold improvements and capital lease equipment, which are depreciated over the shorter of the useful life of the asset or the lease term. Significant additions and improvements that have useful lives estimated at greater than one year are capitalized, while repairs and maintenance are charged to expense as incurred.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for property, plant and equipment which may include the basis of such assets, depreciation methods used and estimated useful lives, the entity's capitalization policy, including its accounting treatment for costs incurred for repairs and maintenance activities, whether such asset balances include capitalized interest and the method by which such is calculated, how disposals of such assets are accounted for and how impairment of such assets is assessed and recognized.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2155824 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 22 -Paragraph 12, 13 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section C -Paragraph 5 -Chapter 9 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 5 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 7 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 34 -Paragraph 8, 9 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Fixed Assets16false 2us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Impairment of Long-Lived Assets</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company evaluates its long-lived assets for indicators of possible impairment by comparison of the carrying amounts to future net undiscounted cash flows expected to be generated by such assets when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Should an impairment exist, the impairment loss would be measured based on the excess carrying value of the asset over the asset's fair value or discounted estimates of future cash flows.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 5 -Section CC -Subsection 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2155824 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 7-15, 26, 30-37 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Impairment of Long-Lived Assets17false 2rptp_AccruedLiabilitiesPolicyPolicyTextBlockrptp_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Accrued Liabilities</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Accrued liabilities include estimates of certain expenses for which the Company has not yet been invoiced and which requires management's judgment in determining appropriate expenses to accrue. For example, because of the nature of how clinical trials are invoiced by clinical sites, especially outside of the U.S. where there is a significant time lag between the services provided by the clinical site and the time the clinical site bills the Company for their services, the Company must estimate such clinical site expenses on a monthly basis as clinical trial expenses. Although the Company believes its accrued liabilities reflect the best information available to it, the Company's actual expenses could differ from its estimates.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for accrued liabilities.No definition available.false0Accrued Liabilities18false 2us-gaap_StockholdersEquityPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Common Stock Warrant Liabilities</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The warrants issued by the Company in the 2010 private placement contain a cash-out provision which may be triggered upon request by the warrant holders if the Company is acquired or upon the occurrence of certain other fundamental transactions involving the Company. This provision requires these warrants to be classified as liabilities and to be marked to market at each period-end commencing on August 31, 2010. The warrants issued by the Company in its December 2009 equity financing contain a conditional obligation that may require the Company to transfer assets to repurchase the warrants upon the occurrence of potential future events. Under FASB ASC Topic 480, <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Distinguishing Liabilities from Equity</font> ("ASC 480")<font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">,</font> a financial instrument that may require the issuer to settle the obligation by transferring assets is classified as a liability. Therefore, the Company has classified the warrants as liabilities and will mark them to fair value at each period end. The common stock warrants are re-measured at the end of every reporting period with the change in value reported in the Company's Condensed Consolidated Statements of Comprehensive Loss. Warrants which are recorded as liabilities that are exercised are re-measured and marked to market the day prior to exercise. Upon exercise of such warrants, the fair value of such warrants is reclassified to equity.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 22 -Paragraph 8 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 false0Common Stock Warrant Liabilities19false 2us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicyus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Deferred Offering Costs</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Deferred offering costs represent expenses incurred to raise equity capital related to financing transactions which have not yet been completed as of the balance sheet dates.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6967983&loc=d3e11264-158415 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 60 -Paragraph 60 -Subparagraph c -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Deferred Offering Costs20false 2us-gaap_DebtPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Note Payable and Debt Issuance Costs</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Note payable consists of the Company's loan agreement with HealthCare Royalty Partners II, L.P. ("HC Royalty"), as lender, under which Raptor agreed to borrow $50.0 million in two $25.0 million tranches. The first tranche was received in December 2012 and the second tranche was received on May 21, 2013. The loan bears interest at an annual fixed rate of 10.75% of outstanding principal and quarterly interest payments are included in interest expense in the Condensed Consolidated Statements of Comprehensive Loss. Principal payments, when made, reduce the note payable balance. There is a synthetic royalty component based on net product sales, including PROCYSBI, in a calendar year, and such royalty is payable quarterly. The royalty fees payable to HC Royalty are included as interest expense. Debt issuance costs, which were capitalized and included in other long-term assets, are being amortized over the life of the loan using the effective interest method. The amortization of debt issuance costs is included in interest expense in the Condensed Consolidated Statements of Comprehensive Loss.</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for costs incurred to obtain or issue debt, the effects of refinancings, method of amortizing deferred financing costs and original issue discount, and classifications of debt on the balance sheet.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2208565 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 22 -Paragraph 8, 12 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Note Payable and Debt Issuance Costs21false 2us-gaap_ResearchAndDevelopmentExpensePolicyus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Research and Development Costs</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Research and development costs are charged to expense as incurred. Research and development expenses include medical, clinical, regulatory and scientists' salaries and benefits, lab collaborations, preclinical studies, clinical trials, clinical trial materials, commercial drug manufacturing prior to obtaining marketing approval, regulatory and clinical consultants, lab supplies, lab services, lab equipment maintenance and small equipment purchased to support the research laboratory, amortization of intangible assets and allocated human resources and facilities expenses. Research and development expenses are offset by contra-expenses, which are reimbursements of research and development expenses received either from research collaborators or from government grants or tax rebates.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2127266 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Research and Development -URI http://asc.fasb.org/extlink&oid=6523717 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 2 -Paragraph 8, 12, 13 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 6 -Paragraph 5, 6, 8 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 42 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Research and Development Costs22false 2us-gaap_IncomeTaxPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Income Taxes</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Income taxes are recorded under the liability method, under which deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company's effective tax rate is 0% for income tax for the three and six months ended June 30, 2013. The Company has determined that its effective tax rate for fiscal year ended August 31, 2012 and the short tax year from September 1, 2012 to December 31, 2012 is 0%. Based on the weight of available evidence, including cumulative losses since inception and expected future losses, the Company has determined that it is more likely than not that the deferred tax asset amount will not be realized and therefore a full valuation allowance has been provided on the Company's net deferred tax assets.</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Utilization of the Company's net operating loss ("NOL") carryovers may be subject to substantial annual limitation due to the ownership change rules under the Internal Revenue Code and similar state income tax law provisions including those related to the suspension and limitation of NOL carryovers for certain tax years. Such an annual limitation could result in the expiration of the NOL carryovers before utilization.</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company accounts for income taxes under FASB ASC No. 740-10, <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Accounting for Uncertainty in Income Taxes</font>. Under this approach, deferred tax assets and liabilities are recognized based on anticipated future tax consequences, using currently enacted tax laws attributed to temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts calculated for income tax purposes.</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company's continuing practice is to recognize interest and/or penalties related to income tax matters as a component of income tax expense. As of June 30, 2013, there were no accrued interest or penalties related to uncertain tax positions. As of June 30, 2013, there were no unrecognized tax benefits for which the liability for such taxes were recognized as deferred liabilities.</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Company files U.S. Federal, California and other state income tax returns. In addition, the Company files income tax returns in France and the Netherlands. The Company is currently not subject to any income tax examinations. Due to the Company's NOLs, generally all tax years remain open.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 4 -Paragraph 11 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 48 -Paragraph 20 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32247-109318 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 30 -URI http://asc.fasb.org/subtopic&trid=2144749 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 954 -SubTopic 740 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2144681 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 17 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32280-109318 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 6-34, 43, 47, 49 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Income Taxes23false 2us-gaap_EarningsPerSharePolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss per Share</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Net loss per share is calculated by dividing net loss by the weighted-average shares of common stock outstanding during the period. Diluted net income per share is calculated by dividing net income by the weighted-average shares of common stock outstanding and potential shares of common stock during the period. For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted net loss per share as their effect is anti-dilutive. Potentially dilutive securities include:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 48.83%; vertical-align: top;"><div>&#160;</div></td><td style="width: 4.31%; vertical-align: top;"><div>&#160;</div></td><td colspan="6" style="border-bottom: #000000 2px solid; width: 42.56%; vertical-align: top;"><div style="text-align: center; font-family: ''times new roman'', times, serif; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">For the six months ended</div></td><td style="width: 4.31%; vertical-align: top;"><div>&#160;</div></td></tr><tr><td style="border-bottom: #000000 2px solid; width: 48.83%; vertical-align: top;"><div style="text-align: left; font-style: italic; font-family: ''times new roman'', times, serif; font-size: 10pt; font-weight: bold; margin-right: 3.15pt;">(In thousands)</div></td><td style="width: 4.31%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">&#160;</div></td><td colspan="2" style="border-bottom: #000000 2px solid; width: 18.02%; vertical-align: top;"><div style="text-align: center; font-family: ''times new roman'', times, serif; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">June 30, 2013</div></td><td style="width: 3.39%; vertical-align: top;"><div>&#160;</div></td><td style="width: 3.39%; vertical-align: top;"><div>&#160;</div></td><td colspan="2" style="border-bottom: #000000 2px solid; width: 17.76%; vertical-align: top;"><div style="text-align: center; font-family: ''times new roman'', times, serif; font-size: 10pt; font-weight: bold; margin-right: 1.8pt;">May 31, 2012</div></td><td style="width: 4.31%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; font-weight: bold; margin-right: 0.8pt;">&#160;</div></td></tr><tr><td bgcolor="#cceeff" style="width: 48.83%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 3.15pt;">Warrants to purchase common stock</div></td><td bgcolor="#cceeff" style="width: 4.31%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td bgcolor="#cceeff" style="width: 4.78%; vertical-align: top;"><div style="text-align: right; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td bgcolor="#cceeff" style="width: 13.25%; vertical-align: top;"><div style="text-align: right; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">2,213</div></td><td bgcolor="#cceeff" style="width: 3.39%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#cceeff" style="width: 3.39%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#cceeff" style="width: 3.92%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#cceeff" style="width: 13.84%; vertical-align: top;"><div style="text-align: right; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">5,188</div></td><td bgcolor="#cceeff" style="width: 4.31%; vertical-align: top;"><div style="text-align: right; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td></tr><tr><td bgcolor="#ffffff" style="width: 48.83%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 3.15pt;">Options to purchase common stock</div></td><td bgcolor="#ffffff" style="width: 4.31%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td bgcolor="#ffffff" style="width: 4.78%; vertical-align: top;"><div style="text-align: right; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td bgcolor="#ffffff" style="border-bottom: #000000 2px solid; width: 13.25%; vertical-align: top;"><div style="text-align: right; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">8,336</div></td><td bgcolor="#ffffff" style="width: 3.39%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#ffffff" style="width: 3.39%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#ffffff" style="width: 3.92%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#ffffff" style="border-bottom: #000000 2px solid; width: 13.84%; vertical-align: top;"><div style="text-align: right; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">6,095</div></td><td bgcolor="#ffffff" style="width: 4.31%; vertical-align: top;"><div style="text-align: right; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td></tr><tr><td bgcolor="#cceeff" style="width: 48.83%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td bgcolor="#cceeff" style="width: 4.31%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td bgcolor="#cceeff" style="width: 4.78%; vertical-align: top;"><div style="text-align: right; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td bgcolor="#cceeff" style="width: 13.25%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#cceeff" style="width: 3.39%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#cceeff" style="width: 3.39%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#cceeff" style="width: 3.92%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#cceeff" style="width: 13.84%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#cceeff" style="width: 4.31%; vertical-align: top;"><div style="text-align: right; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td></tr><tr><td bgcolor="#ffffff" style="width: 48.83%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 3.15pt;">Total potentially dilutive securities</div></td><td bgcolor="#ffffff" style="width: 4.31%; vertical-align: top;"><div style="text-align: left; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td bgcolor="#ffffff" style="width: 4.78%; vertical-align: top;"><div style="text-align: right; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td><td bgcolor="#ffffff" style="border-bottom: #000000 4px double; width: 13.25%; vertical-align: top;"><div style="text-align: right; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">10,549</div></td><td bgcolor="#ffffff" style="width: 3.39%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#ffffff" style="width: 3.39%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#ffffff" style="width: 3.92%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#ffffff" style="border-bottom: #000000 4px double; width: 13.84%; vertical-align: top;"><div style="text-align: right; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">11,283</div></td><td bgcolor="#ffffff" style="width: 4.31%; vertical-align: top;"><div style="text-align: right; font-family: ''times new roman'', times, serif; font-size: 10pt; margin-right: 0.8pt;">&#160;</div></td></tr><tr><td bgcolor="#cceeff" style="width: 48.83%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#cceeff" style="width: 4.31%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#cceeff" style="width: 4.78%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#cceeff" style="width: 13.25%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#cceeff" style="width: 3.39%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#cceeff" style="width: 3.39%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#cceeff" style="width: 3.92%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#cceeff" style="width: 13.84%; vertical-align: top;"><div>&#160;</div></td><td bgcolor="#cceeff" style="width: 4.31%; vertical-align: top;"><div>&#160;</div></td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Net loss per share, basic and diluted, was $(0.43) and $(0.06) for the three months ended June 30, 2013 and May 31, 2012, respectively, and $(0.73) and $(0.35) for the six months ended June 30, 2013 and May 31, 2012, respectively.</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2144384 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 6, 8-16, 60 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Net Loss per Share24false 2us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicyus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"><font style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</font><!--Anchor--><font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Stock Option Plan</font></div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Effective September 1, 2006, the Company adopted the provisions of FASB ASC Topic 718, <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Accounting for Compensation Arrangements</font>, ("ASC 718") (previously listed as Statement of Financial Accounting Standards ("SFAS") No. 123 <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(revised 2004), Share-Based Payment)</font> in accounting for its stock option plans. Under ASC 718, compensation cost is measured at the grant date based on the fair value of the equity instruments awarded and is recognized over the period during which an employee is required to provide service in exchange for the award, or the requisite service period, which is usually the vesting period. The fair value of the equity award granted is estimated on the date of the grant. The Company accounts for stock options issued to third parties, including consultants, in accordance with the provisions of the FASB ASC Topic 505-50, <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Equity-Based Payments to Non-Employees,</font> ("ASC 505-50") (previously listed as Emerging Issues Task Force Consensus No. 96-18, <font style="font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling Goods or Services).</font> See Note 7, Stock Option Plans, for further discussion of employee stock-based compensation.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">For the quarter ended June 30, 2013, stock-based compensation expense was based on the Black-Scholes option-pricing model assuming the following: risk-free interest rate of 0.92%; five year expected life; 78% volatility; 2.5% turnover rate; and 0% dividend rate.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Black-Scholes inputs were based on the following factors:</div><div><br /></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 36pt; vertical-align: top; align: right;"><div style="text-align: left; font-family: symbol, serif; margin-left: 18pt; font-size: 10pt;">&#183;</div></td><td style="width: auto; vertical-align: top;"><div style="text-align: justify; font-family: ''times new roman'', times, serif; font-size: 10pt;">the risk-free interest rate was based upon the Company's review of current constant maturity treasury bill rates for five years;</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 36pt; vertical-align: top; align: right;"><div style="text-align: left; font-family: symbol, serif; margin-left: 18pt; font-size: 10pt;">&#183;</div></td><td style="width: auto; vertical-align: top;"><div style="text-align: justify; font-family: ''times new roman'', times, serif; font-size: 10pt;">the expected life of five years was based upon the Company's assessment of the ten-year term of the stock options issued along with the fact that the Company is a commercial company and anticipates that option holders will commence exercising stock options that are fully vested;</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 36pt; vertical-align: top; align: right;"><div style="text-align: left; font-family: symbol, serif; margin-left: 18pt; font-size: 10pt;">&#183;</div></td><td style="width: auto; vertical-align: top;"><div style="text-align: justify; font-family: ''times new roman'', times, serif; font-size: 10pt;">the volatility was based on the actual annualized volatility of the Company's common stock price as quoted on NASDAQ since the closing of the 2009 Merger on September 30, 2009;</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 36pt; vertical-align: top; align: right;"><div style="text-align: left; font-family: symbol, serif; margin-left: 18pt; font-size: 10pt;">&#183;</div></td><td style="width: auto; vertical-align: top;"><div style="text-align: justify; font-family: ''times new roman'', times, serif; font-size: 10pt;">the turnover rate was based on an assessment of the Company's historical employee turnover; and</div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 36pt; vertical-align: top; align: right;"><div style="text-align: left; font-family: symbol, serif; margin-left: 18pt; font-size: 10pt;">&#183;</div></td><td style="width: auto; vertical-align: top;"><div style="text-align: justify; font-family: ''times new roman'', times, serif; font-size: 10pt;">the dividend rate was based on the Company's current decision to not pay dividends on its stock during its current stage.</div></td></tr></table></div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div></div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b),(f) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2228939 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 06-11 -Paragraph 7 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Stock Option Plan25false 2us-gaap_Reclassificationsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Reclassifications</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Certain amounts previously reported under specific financial statement captions have been reclassified to be consistent with the current period presentation.</div></div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section A -Paragraph 2 -Chapter 2 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0ReclassificationsfalseDESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://raptorpharma.com/role/DescriptionOfBusinessAndSignificantAccountingPoliciesPolicies125